A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

This publication has 22 references indexed in Scilit:

• The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progressionin vitroandin vivo
  Molecular Cancer Therapeutics, 2007
• Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients
  British Journal of Clinical Pharmacology, 2006
• Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast Cancer
  Clinical Cancer Research, 2005
• Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
  Cancer, 2005
• Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase
  Journal of Clinical Oncology, 2005
• Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity
  Clinical Cancer Research, 2004
• Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI‐277 on inhibition of MCF‐7 breast cancer cell‐cycle progression
  International Journal of Cancer, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
  Endocrine-Related Cancer, 1999
• Aberrant function of the Ras signal transduction pathway in human breast cancer
  Breast Cancer Research and Treatment, 1995